Acute Coronary Syndromes

Acute coronary syndrome (ACS) is most commonly caused by a heart attack (myocardial infarction) where blood flow to the heart is suddenly blocked. This is usually caused by a blood clot from a ruptured coronary artery atherosclerotic plaque. Other causes include spontaneous coronary artery dissection (SCAD), which most commonly occurs in women. ACS is usually treated in a cath lab with angioplasty and the placement of a stent to prop the vessel open.

RSS icon
AI artificial intelligence stethoscope doctor

AI model outperforms researchers’ ‘wildest dreams’ with accurate heart attack assessments

The algorithm, developed using data from more than 7,00 chest pain patients, performed better than multiple techniques currently used to evaluate cardiac events. 

Colchicine Lodoco Agepha Pharma price cost

What will Lodoco cost? Looking ahead after FDA’s historic approval of colchicine for CVD

“Our pricing strategy for Lodoco is focused on helping to ensure access to as many people as possible,” an executive with Agepha Pharma told Cardiovascular Business. 

The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment.

Cardiologists applaud FDA’s approval of colchicine for CVD

"The FDA's approval of colchicine confirms that we are entering a new era of patient care," said one veteran cardiologist familiar with the drug. 

The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment.

FDA approves colchicine, the first anti-inflammatory drug for treating cardiovascular disease

The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.

healthcare value value-based care money dollar

Bitterroot Bio, a new biotech company launched by physicians and industry veterans, raises $145M

The new company formed in 2021, but waited until now to publicly launch. Its founders included two Stanford University physicians.

Thumbnail

FDA announces recall of certain Impella heart pumps after 3 patient injuries, nearly 200 complaints

The FDA has labeled this as a Class I recall, which means using these devices can lead to significant injuries, including death.

Regularly eating avocados is associated with a reduced risk of cardiovascular disease, according to a new study.

Plant-based diets—both vegetarian and vegan—linked to lower cholesterol levels, reduced risk of blocked arteries

A new systematic review and meta-analysis of 30 RCTs highlighted numerous benefits associated with vegetarian and vegan diets. Combining a plant-based diet with statin therapy, one researcher noted, could result "in an even larger beneficial effect.”

Imaging results more helpful than genetics when predicting heart disease, new head-to-head study confirms

The new analysis, published in JAMA, suggests that CT results can help identify medium- and high-risk patients who may need to be considered for statin therapy or other preventive treatments.

Displaying 137 - 144 of 667

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.